Literature DB >> 9548489

Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein.

M Tolnay1, J D Lambris, G C Tsokos.   

Abstract

Complement receptor 2 (CR2) has been implicated as a regulator of B cell function. In this study, we sought to identify mechanisms that control the expression of the CR2 gene in human B cells. Dibutyryl cAMP increased the DNA-binding activity of a nuclear protein that recognized specifically a CR2 promoter-defined oligonucleotide in human B cell lines. The nuclear protein was subsequently purified from B cell nuclear extracts using a biotinylated CR2 promoter-defined oligonucleotide. Partial amino acid sequence analysis of internal peptides revealed that the 42-kDa protein belongs to a family of heterogeneous nuclear ribonucleoproteins (hnRNP). Using a set of mutated double-stranded oligonucleotides, we demonstrated that the purified protein displayed sequence specificity for the CR2 promoter-defined oligonucleotide. Like some hnRNP, this protein was found to bind to single-stranded DNA. The DNA-binding activity of the purified protein increased after in vitro phosphorylation with protein kinase A. Using a CAT reporter gene driven by a single recognition site in B cell lines, dibutyryl cAMP caused a 3-fold induction of reporter gene expression. The highest induction (6.7-fold) was achieved with a combination of dibutyryl cAMP and PMA. The involvement of the nuclear protein in regulating the expression of the CR2 gene is supported by our finding that dibutyryl cAMP increased the levels of the CR2 mRNA and CR2 surface membrane protein in human B cell lines. These data strongly suggest that a cAMP-inducible hnRNP, which can recognize a novel DNA-motif, controls the expression of the CR2 gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9548489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  LC/MS identification of 12 intracellular cytoskeletal and inflammatory proteins from monocytes adherent on surface-adsorbed fibronectin-derived peptides.

Authors:  Sean T Zuckerman; Weiyuan John Kao
Journal:  J Biomed Mater Res A       Date:  2008-05       Impact factor: 4.396

3.  Protein kinase A enhances, whereas glycogen synthase kinase-3 beta inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion.

Authors:  Mate Tolnay; Yuang-Taung Juang; George C Tsokos
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

4.  Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains.

Authors:  M Tolnay; L Baranyi; G C Tsokos
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

5.  Upf1/Upf2 regulation of 3' untranslated region splice variants of AUF1 links nonsense-mediated and A+U-rich element-mediated mRNA decay.

Authors:  Lili Banihashemi; Gerald M Wilson; Neha Das; Gary Brewer
Journal:  Mol Cell Biol       Date:  2006-09-25       Impact factor: 4.272

6.  Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein.

Authors:  M Tolnay; L A Vereshchagina; G C Tsokos
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

7.  Heterogeneous nuclear ribonucleoprotein D/AUF1 interacts with heterogeneous nuclear ribonucleoprotein L.

Authors:  Hong-Gyu Park; Ji-Young Yoon; Mieyoung Choi
Journal:  J Biosci       Date:  2007-12       Impact factor: 1.826

8.  Control of estradiol-directed gene transactivation by an intracellular estrogen-binding protein and an estrogen response element-binding protein.

Authors:  Hong Chen; Martin Hewison; John S Adams
Journal:  Mol Endocrinol       Date:  2007-12-20

9.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.